US › Healthcare

Standard Biotools Inc (LAB)

US · Healthcare · Medical Devices

$0.82-5.28%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$21.1M
Revenue YoY
+4.6%
Net profit
$-45.2M
Profit YoY
-73.7%
EPS
$-0.02
EPS estimate
$-0.02
Net margin
-213.9%

EPS came in at -0.02 against a street estimate of -0.02 — a beat of 0.0%.

Key statistics

Market cap
$339.8M
Forward P/E
0.0
P/B
0.61
Book value
$1.44
EPS (TTM)
$-0.13
52-week high
$1.72
52-week low
$0.70
50-day MA
$0.91
200-day MA
$1.13
Beta
1.42

Analyst view

Analysts rate Standard Biotools Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $1.55.

Shareholding

Insiders
2.16%
Institutions
76.69%

Largest institutional holders

FundStake
Casdin Capital, LLC22.68%
Viking Global Investors LP14.98%
Mak Capital One LLC6.69%
BlackRock Inc6.32%
Long Focus Capital Management, LLC4.09%
Vanguard Capital Management, LLC3.27%
Geode Capital Management, LLC1.86%
State Street Corp1.67%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Standard Biotools Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.